In vitro-in vivo correlations: General principles and methodologies, regulatory aspects and applications (Part 2)

Pharmazeutische Industrie

Volumn 75, Issue 2, 2013, Pages 312-318

  Hühn, Eva ^a   Langguth, Peter ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; CURVE FITTING; DOSIMETRY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG RELEASE; DRUG SOLUBILITY; INTRAVENOUS ADMINISTRATION; LAPLACE TRANSFORMATION; LOO RIEGELMAN METHOD; MASS BALANCE METHOD; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MEASUREMENT ERROR; ORAL DRUG ADMINISTRATION; PLASMA CONCENTRATION-TIME CURVE; REGRESSION ANALYSIS; STOCHASTIC MODEL; WAGNER NELSON METHOD;

EID: 84876587731     PISSN: 0031711X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Wagner JG, VeldkampW, Long S. Correlation of in vivo with in vitro disintegration times of enteric coated tablets. J Am Pharm Assoc Am Pharm Assoc (Baltim). 1958 Sep;47(9):681-5.
2. Smolen VF. Theoretical and computational basis for drug bioavailability determinations using pharmacological data. I. General considerations and procedures. J Pharmacokinet Biopharm. 1976 Aug;4(4):337-53. (Pubitemid 8122216)
3. United States Pharmacopeial Convention. Pharmacopeial Forum Stimuli Article. In Vitro/In Vivo Correlation for Extended Release Oral Dosage Forms. 1988. 4160-4161.
4. United States Pharmacopeial Convention. USP 23 <1088>. In Vitro and In Vivo Evaluation of Dosage Forms. 1995. 1924-1929.
5. U.S. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Guidance for Industry. Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. 1997. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070239.pdf
6. European Medicines Agency (EMA). Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Quality of Modified Release Products A) Oral Solid Dosage Forms B) Transdermal Dosage Forms Section I (Quality). 1999. CPMP/QWP/604/96. Available from: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003664.pdf
7. U.S. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Guidance for Industry. Dissolution Testing of Immediate Release Solid Oral Dosage Forms. 1997. Available from: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070237.pdf
8. U.S. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Guidance for Industry. SUPAC-IR: Immediate Release Solid Oral Dosage Forms. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. 1995. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070636.pdf
9. U.S. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Guidance for Industry. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. 2000. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070246.pdf
10. U.S. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Guidance for Industry. SUPAC-MR: Modified Release Solid Oral Dosage Forms. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. 1997. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070640.pdf
11. U.S. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. 2003. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070124.pdf
12. European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. 2010. CPMP/EWP/QWP/1401/98 Rev. 1. Available from: http://www.ema.europa.eu/docs/en- GB/document-library/Scientific-guideline/2010/01/WC500070039.pdf
13. European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP). Concept paper on the revision of the note for guidance on quality of modified release oral dosage forms and transdermal dosage forms: Section I (quality). 2010 EMA/CHMP/QWP/202350/2010. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/ 07/WC500095366.pdf
14. United States Pharmacopeial Convention. USP 34 <1088>. In Vitro and In Vivo Evaluation of Dosage Forms. 2011. 612-617.
15. Mitra A, Wu Y. Use of In Vitro-In Vivo Correlation (IVIVC) to facilitate the development of polymer-based controlled release injectable formulation. Recent Pat Drug Deliv Formul. 2010 Jun;4(2):94-104.
16. Martinez M, Rathbone M, Burgess D, Huynh M. In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting. J Control Release. 2008 Jul 14;129(2):79-87.
17. Burgess DJ, Crommelin DJ, Hussain AS, Chen ML. Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS PharmSci. 2004 Mar 22;6(1):E11.
18. Burgess DJ, Hussain AS, Ingallinera TS, Chen ML. Assuring quality and performance of sustained and controlled release parenterals: workshop report. AAPS PharmSci. 2002;4(2):E7.
19. Brockmeier D, Dengler HJ, Voegele D. In vitro-in vivo correlation of dissolution, a time scaling problem? Transformation of in vitro results to the in vivo situation, using theophylline as a practical example. Eur J Clin Pharmacol. 1985;28(3):291-300. (Pubitemid 15085155)
20. Shepard T, Farrell CA. A theoretical evaluation of the PDx-IVIVC equation: Applicability and limitations. AAPS Annual Meeting 2002 Toronto, Canada. 2002.
21. Mendell-Harary J, Dowell J, Bigora S, Piscitelli D, Butler J, Farrell C, et al. Nonlinear in vitro-in vivo correlations. Adv Exp Med Biol. 1997;423:199-206. (Pubitemid 27347205)
22. Wagner JG, Nelson E. Per cent absorbed time plots derived from blood level and/or urinary excretion data. J Pharm Sci. 1963 Jun;52:610-1.
23. Loo JC, Riegelman S. New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci. 1968 Jun;57(6):918-28.
24. Langenbucher F, Moeller H. Correlation of in vitro drug release with in vivo response kinetics. Pharm Ind. 1983;45(6):623-28.
25. Langenbucher F. Handling of computational in vitro/in vivo correlation problems by Microsoft Excel: III. Convolution and deconvolution. Eur J Pharm Biopharm. 2003 Nov;56(3):429-37. (Pubitemid 37346517)
26. Vaughan DP, Dennis M. Mathematical basis of point-area deconvolution method for determining in vivo input functions. J Pharm Sci. 1978 May;67(5):663-5. (Pubitemid 8364971)
27. Chiou WL. New compartment- and model-independent method for rapid calculation of drug absorption rates. J Pharm Sci. 1980 Jan; 69(1):57-62. (Pubitemid 10136821)
28. Gamel J, Rousseau WF, Katholi CR, Mesel E. Pitfalls in digital computation of the impulse response of vascular beds from indicator-dilution curves. Circ Res. 1973 Apr;32(4):516-23.
29. Cutler DJ. Numerical deconvolution by least squares: use of prescribed input functions. J Pharmacokinet Biopharm. 1978 Jun; 6(3):227-41. (Pubitemid 8379262)
30. Cutler DJ. Numerical deconvolution by least squares: use of polynomials to represent the input function. J Pharmacokinet Biopharm. 1978 Jun;6(3):243-63. (Pubitemid 8379263)
31. Veng-Pedersen P. An algorithm and computer program for deconvolution in linear pharmacokinetics. J Pharmacokinet Biopharm. 1980 Oct;8(5):463-81. (Pubitemid 11136585)
32. Gillespie WR, Veng-Pedersen P. A polyexponential deconvolution method. Evaluation of the "gastrointestinal bioavailability" and mean in vivo dissolution time of some ibuprofen dosage forms. J Pharmacokinet Biopharm. 1985 Jun;13(3):289-307. (Pubitemid 16194626)
33. Veng-Pedersen P. Noncompartmentally-based pharmacokinetic modeling. Adv Drug Deliv Rev. 2001 Jun 11;48(2-3):265-300. (Pubitemid 32434407)
34. Verotta D. Two constrained deconvolution methods using spline functions. J Pharmacokinet Biopharm. 1993 Oct;21(5):609-36. (Pubitemid 24037113)
35. Verotta D. Estimation and model selection in constrained deconvolution. Ann Biomed Eng. 1993 Nov-Dec;21(6):605-20. (Pubitemid 24026379)
36. Kiwada H, Morita K, Hayashi M, Awazu S, Hanano M. A new numerical calculation method for deconvolution in linear compartment analysis of pharmacokinetics. Chem Pharm Bull (Tokyo). 1977 Jun;25(6):1312-8. (Pubitemid 8127160)
37. Fattinger KE, Verotta D. A nonparametric subject-specific population method for deconvolution: I. Description, internal validation, and real data examples. J Pharmacokinet Biopharm. 1995 Dec; 23(6):581-610. (Pubitemid 26155335)
38. Fattinger KE, Verotta D. A nonparametric subject-specific population method for deconvolution: II. External validation. J Pharmacokinet Biopharm. 1995 Dec;23(6):611-34. (Pubitemid 26155336)
39. Mauger DT, Chinchilli VM. In vitro-in vivo relationships for oral extended-release drug products. J Biopharm Stat. 1997 Nov;7(4): 565-78. (Pubitemid 27502174)
40. Dunne A, O'Hara T, Devane J. Level A in vivo-in vitro correlation: nonlinear models and statistical methodology. J Pharm Sci. 1997 Nov;86(11):1245-9. (Pubitemid 27486095)
41. Dunne A, O'Hara T, Devane J. A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption. Stat Med. 1999 Jul 30;18(14):1865-76; discussion 77.
42. O'Hara T, Hayes S, Davis J, Devane J, Smart T, Dunne A. In vivo-in vitro correlation (IVIVC) modeling incorporating a convolution step. J Pharmacokinet Pharmacodyn. 2001 Jun;28(3):277-98. (Pubitemid 32643368)
43. Gillespie WR. Convolution-based approaches for in vivo-in vitro correlation modeling. Adv Exp Med Biol. 1997;423:53-65. (Pubitemid 27347192)
44. Langenbucher F. Numerical convolution/deconvolution as a tool for correlating in vitro with in vivo drug availability. Pharm Ind. 1982;44(11):1166-72. (Pubitemid 13137274)
45. Dunne A, Gaynor C, Davis J. Deconvolution based approach for level A in vivo-in vitro correlation modelling: statistical considerations. Clin Res Regul Aff. 2005;22(1):1-14. (Pubitemid 40756840)
46. Gaynor C, Dunne A, Davis J. A comparison of the prediction accuracy of two IVIVC modelling techniques. J Pharm Sci. 2008 Aug; 97(8):3422-32.
47. Hovorka R, Chappell MJ, Godfrey KR, Madden FN, Rouse MK, Soons PA. CODE: a deconvolution program implementing a regularization method of deconvolution constrained to non-negative values. Description and pilot evaluation. Biopharm Drug Dispos. 1998 Jan; 19(1):39-53. (Pubitemid 28064490)
48. Dowell JA, Hussain A, Devane J, Young D. Artificial neural networks applied to the in vitro-in vivo correlation of an extended-release formulation: initial trials and experience. J Pharm Sci. 1999 Jan; 88(1):154-60. (Pubitemid 29037384)
49. Parojcic J, Ibric S, Djuric Z, Jovanovic M, Corrigan OI. An investigation into the usefulness of generalized regression neural network analysis in the development of level A in vitro-in vivo correlation. Eur J Pharm Sci. 2007 Mar;30(3-4):264-72.
50. Yamashita F, Fujita A, Zhang X, Sasa Y, Mihara K, Hashida M. Computer-based Evolutionary Search for a Nonlinear Conversion Function for Establishing In Vitro-In Vivo Correlation (IVIVC) of Oral Drug Formulations. Drug Metab Pharmacokinet. 2012 Jun 25;27(3):280-5.
51. Lukacova V, Woltosz WS, Bolger MB. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. Aaps J. 2009 Jun;11(2):323-34.
52. Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, et al. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2011 May;50(5):331-47.
53. Cook JA. A technique to estimate in vivo dissolution profiles without data from a solution. Aaps J. 2012 Sep;14(3):433-6.
54. Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J Pharm Sci. 2011 Dec;100(12):5324-45.
55. Thelen K, Coboeken K, Willmann S, Dressman JB, Lippert J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms. J Pharm Sci. 2012 Mar;101(3):1267-80.